US company’s patent bid for life-saving TB therapy nixed

The Indian Patent Office has rejected a patent application by US-based Global Alliance for TB Drug Development for BPaL, a life-saving tuberculosis therapy, citing lack of novelty and inventive step. The decision could allow domestic drugmakers to launch cheaper generic versions in India and other high-burden countries, health experts said.